Real-World Data on Combined EGFR-TKI and Crizotinib Treatment for Acquired and De Novo <i>MET</i> Amplification in Patients with Metastatic <i>EGFR</i>-Mutated NSCLC by Edyta M. Urbanska, Morten Grauslund, Peter R. Koffeldt, Sarah L. B. Truelsen, Johan O. Löfgren, Junia C. Costa, Linea C. Melchior, Jens B. Sørensen, Eric Santoni-Rugiu

Get full text